Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
HIV MT-4 Serum Shift Antiviral Reporter Assay from US Patent US11613546: "Substituted pyridotriazine compounds and uses thereof"
Assay data:83 Active, 14 Activity ≤ 1 nM, 83 Activity ≤ 1 µM, 83 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
CD4 mimetic activity at gp120 in HIV-1 KP-5mvcR infected in human TZM-bl cells assessed as inhibition of viral entry by measuring reduction in RLU by single round assay
Assay data:5 Active, 2 Activity ≤ 1 µM, 11 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of HIV1 gp120 interaction with CD4 pretreated for 1 hr followed by TMB substrate addition and measured after 10 mins by ELISA
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
MT-4 HIV High Resolution Antiviral Assay from US Patent US10774053: "HIV protease inhibitors"
Assay data:350 Active, 339 Activity ≤ 1 µM, 351 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Mt-4 HIV Assay from US Patent US10774053: "HIV protease inhibitors"
Assay data:347 Active, 345 Activity ≤ 1 µM, 347 Tested
Inhibition of HIV replication from US Patent US10189816: "Substituted pyridines as inhibitors of human immunodeficiency virus replication"
Assay data:162 Active, 162 Activity ≤ 1 µM, 162 Tested
Infectivity Assay from US Patent US10065953: "Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication"
Assay data:17 Active, 17 Activity ≤ 1 µM, 17 Tested
MT4 Cell Antiviral Assay from US Patent US10064873: "Compounds and compositions for treating HIV with derivatives of Betulin"
Assay data:74 Active, 5 Activity ≤ 1 nM, 74 Activity ≤ 1 µM, 74 Tested
HIV cell culture assay from US Patent US10047118: "C17-aryl substituted betulinic acid analogs"
Assay data:2 Active, 7 Activity ≤ 1 µM, 7 Tested
Anti-HIV Cytoprotection Assay from US Patent US9694024: "Methods of treating retroviral infections and related dosage regimes"
Assay data:2 Active, 2 Activity ≤ 1 µM, 5 Tested
Mimetic activity of CD4 at gp120 in HIV-1 ADA infected in CD4-negative dog Cf2Th-CCR5 cells assessed as agonism of viral entry by measuring enhancement of viral infection at 20 to 60 uM pretreated for 30 mins before viral infection and incubated for 48 hrs by luciferase assay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of gp120 in HIV-1 ADA infected in CD4-negative dog Cf2Th-CCR5 cells assessed as antagonism of viral entry by measuring inhibition of viral infection at 20 to 60 uM pretreated for 30 mins before viral infection and incubated for 48 hrs by luciferase assay
Assay data:3 Active, 3 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of gp120 in HIV-1 subtype B #11578 harboring pseudotyped Env pWEAUd15.410.5017 infected in human TZM-bl cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based single cycle infection assay
Assay data:8 Active, 1 Activity ≤ 1 µM, 32 Tested
Inhibition of gp120 in HIV-1 191084 infected in dog Cf2Th-CD4/CCR5 cells assessed as inhibition of viral entry incubated for 30 mins prior to infection and and further incubated for 48 to 72 hrs in presence of firefly D-luciferin free acid and ATP by single-round infection luciferase assay
Assay data:2 Tested
Inhibition of gp120 in HIV-1 A4 infected in dog Cf2Th-CD4/CCR5 cells assessed as inhibition of viral entry incubated for 30 mins prior to infection and and further incubated for 48 to 72 hrs in presence of firefly D-luciferin free acid and ATP by single-round infection luciferase assay
Inhibition of gp120 in HIV-1 pseudotyped with A-MLV envelop glycoprotein infected in dog Cf2Th-CD4/CCR5 cells assessed as inhibition of viral entry incubated for 30 mins prior to infection and and further incubated for 48 to 72 hrs in presence of firefly D-luciferin free acid and ATP by single-round infection luciferase assay
Assay data:11 Tested
Inhibition of gp120 in HIV-1 AD8 infected in dog Cf2Th-CD4/CCR5 cells assessed as inhibition of viral entry incubated for 30 mins prior to infection and and further incubated for 48 to 72 hrs in presence of firefly D-luciferin free acid and ATP by single-round infection luciferase assay
Assay data:9 Active, 2 Activity ≤ 1 µM, 9 Tested
Inhibition of HIV1 KP-5mvcR gp120 interaction with CD4 in human TZM-bl cells assessed as decrease in viral entry at 0.1 uM by MTT assay relative to control
Inhibition of HIV1 KP-5mp1 gp120 interaction with CD4 human TZM-bl cells assessed as decrease in viral entry by MTT assay
Assay data:6 Active, 9 Tested
Inhibition of HIV1 KP-5mvcR gp120 interaction with CD4 in human TZM-bl cells assessed as decrease in viral entry by MTT assay
Assay data:17 Active, 15 Activity ≤ 1 µM, 18 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on